Introduction: Greatly increased use of antifungal therapies has resulted in the development of multidrug resistant. The phenolic compound carvacrol have been reported to have anti-Candida activity. This work is an attempt to examine effect of carvacrol on ergosterol synthesis against multidrug resistant Candida albicans.
polyenes, azoles, allylamines, echinocandins and miazines. Their target mechanisms are inhibiting or interfering with cell membrane or cell wall and inhibiting DNA synthesis (2) (3) (4) .
The increased use of antifungal agents has led to multiple exposures of Candida species to these drugs with a resulting development of multidrug resistant. In addition, serious side effects include nephrotoxicity, visual disturbances, congestive heart failure caused by antifungal drugs. Moreover, some of these drugs are in limited clinical use due to high costs (2, 4, 5) .
Resistance isolates of C. albicans poses a serious threat to therapy and as a result has initiated a search for identifying new antifungal agents that could be used to treat the infections. In the recent years, antifungal compounds of natural origin, such as carvacrol, have received particular attention. They are a promising therapeutic strategy for fungal infections. Carvacrol [C6H3CH3(OH)(C3H7)], is a monoterpenoid phenol compound of the essential oils produced by of the Lamiaceae family. Results from in vitro and in vivo studies show that carvacrol possess antifungal activity against C. albicans (6-13). Vardar-Unlu et al (12) the in vitro activity of carvacrol on 100 clinical isolates of C. albicans was evaluated. MIC50 and MIC90 values of carvacrol were observed at 64 and 125 µg/ml, respectively. Chami et al (13) demonstrated that the carvacrol and eugenol could be considered as strong antifungal agents in the treatment of experimental oral candidiasis induced by C. albicans in immune-suppressed rats.
Carvacrol exerts its effect on the cell membrane instability by targeting and binding ergosterol in C. albicans (6, 8, 14) . The ergosterol and its biosynthetic pathway is essential for fungal growth. This pathway includes ratelimiting enzyme, lanosterol 14α-demethylase, which is essential in the ergosterol synthesis in fungi. Lanosterol 14-demethylase is a member of cytochrome P450 enzyme family encoded by the ERG11 gene. This enzyme is involved in the conversion of lanosterol to ergosterol, which catalyses the oxidative removal of the 14α-methyl group from lanosterol (15, 16) .
In the present study, we attempted to evaluate the antifungal effect of carvacrol on ergosterol synthesis in multidrug resistant C. albicans. For this, we performed antifungal susceptibility, time kill assay, hypha formation, ergosterol content and gene expression profiling of multidrug resistant C. albicans.
Methods:
In this cross sectional study during a 6-month period in 2016-2017, various clinical samples such as vagina, mouth and skin surface swabs were collected from 30 immuno-compromised patients (diabetes, cancer and maintenance hemodialysis patients) who admitted in Shahid Beheshti hospital affiliated to Yasooj University of Medical Sciences and informed consent was obtained from patients. Clinical samples transported to the laboratory immediately. This study was approved by Research Ethics Committee of our institute (Ethical code 1280679) (The study protocol conformed to the ethical guidelines of the 2008 Declaration of Helsinki). Colonizing clinical isolates were routinely cultured in Sabouraud dextrose agar (SDA, Difco Laboratories, Detroit, Michigan). All the isolates were identified by conventional (including microscopic and macroscopic morphology, germ tube formation, carbohydrate assimilations, carbohydrate fermentation and urease test) and molecular method (using the universal fungal primers ITS1 and ITS4). Candida colonies were plated on CHROMagar™ Candida (CHROMagar, France) to check for purity and screening for green colonies (16) . Reference strains of C. albicans ATCC 10231 and C. albicans CBS 5982 were employed. In addition, CSLI disk diffusion (M44-A2) and broth microdilution antifungal susceptibility tests (M27-A3 and M27-S4) were used to detect drug (amphotericin B, fluconazole, ketoconazole and miconazole) resistant isolates of C. albicans. The antimicrobial susceptibility test results were analyzed using WHONET software (17) (18) (19) .
In vitro susceptibility to carvacrol (SigmaAldrich Co. St. Louis, MO, USA) were determined using broth dilution antifungal susceptibility test in accordance with CLSI M27-A3. Inoculum suspensions were prepared in sterile 0.85% NaCl and standardized spectrophotometrically at 530 nm (10 6 CFU/ml). This inoculum was diluted 1:100 in Roswell Park Memorial Institute medium 1640 (RPMI 1640) with 0.2% glucose (Sigma-Aldrich) [buffered to pH 7.0 with 0.165 M morpholinophos-phonyl sulfate (MOPS)] to achieve a final concentration of 0.5-5 × 10 3 CFU/ml, as verified by viable colony counts in SDA. The final concentration for carvacrol was 0.19-400 μg/ml. Test microtiter plates with 96 U wells (Moheb Qazvin, Iran) were incubated for 24 h at 35°C. The MIC endpoint for carvacrol was defined as the lowest concentration at which there was a 50 and 90% inhibition of growth as compared with the carvacrol-free growth control. Growth (carvacrol-free) and sterility (medium alone) control wells were established on each test. The time kill assay of carvacrol against C. albicans was determined at 0, 2, 4, 6, 8, 12, 24, and 48 h of incubation at 35°C by plating 10-fold dilutions on SDA. Carvacrol was used at concentrations ranging from 2×MIC to ¼×MIC (19) .
The suspension of C. albicans cell with a density of 1×10 6 cells/ml was used to inoculate 6-well cell culture plates containing 100 μl carvacrol at concentrations ranging from 2×MIC to ¼×MIC. The cultures were incubated for 90 min at 35°C. Hyphal growth was induced by incubating cultures for 16 h at 35 °C and 200 rpm. The hyphae were washed with PBS and visualized with a Nikon microscope, using a 40× objective (20) .
The ergosterol quantification in the C. albicans cell membrane was performed by method as described by Santos et al. (21) . Briefly, C. albicans colony (cell mass: 25 mg) from an overnight SDA plate culture was added to carvacrol at ranging from 2×MIC to ¼×MIC and incubated at 35°C for 24 h. Three ml of 25% alcoholic potassium hydroxide solution was added to harvested cells and incubated in a water bath at 85°C for 1 h. Thereafter the reaction was cooled to room temperature and a mixture of 1 ml of sterile water and 3 ml of n-heptane (Sigma-Aldrich) was added. The supernatant was removed, and the reading was performed in spectrophotometer at 282 and 230 nm. A calibration curve with standard ergosterol was constructed and used to calculate the amount of ergosterol. The results were expressed as the percentage of ergosterol in comparison with the growth control.
Total RNA was extracted from C. albicans cells treated with carvacrol and fluconazole at concentrations of 2×MIC and 1×MIC using a RNeasy Mini Kit (Qiagen, Hilden, Germany) containing DNase I, as described by the manufacturer. RNA quality and quantity of different samples were estimated by spectrophotometric absorbance in a NanoDrop® ND-1000 spectrophotometer (NanoDrop Technologies Inc., Wilmington, DE). The integrity of total RNA was determined by electrophoresis on a formaldehyde-denaturing agarose gel. Total RNA was reverse transcribed into singlestranded cDNA using a M-MuLV reverse transcriptase and random hexamer oligonucleotides (Fermentas, USA), according to the manufacturer's instructions. Real time PCR was performed using cDNA. Amplification, data acquisition and data analysis were performed on a Bio-Rad Mini Opticon TM system (USA) using ™SYBR Green qPCR Master Mix (Fermentas, EU). The oligonucleotide primers for ERG11 (GenBank accession number X13296) and β actin were listed in Table 1 . Relative quantitation of gene expression was obtained by the Pfaffl method (20, 22) .
Data were analysed using the statistical software SPSS 21.0 for Windows (SPSS Inc., Chicago, IL, USA). Experiments were done in triplicate. Comparisons were performed using one-way ANOVA, with Tukey's test. P≤0.05 was considered to be statistically significant. Kappa coefficient showed that there was high degree of agreement between the results obtained by both disk diffusion and broth microdilution antifungal susceptibility tests. Multidrug resistance was observed in clinical isolates of C. albicans from immunecompromised patients. The resistance rates of clinical isolates of C. albicans for amphotericin B, fluconazole, ketoconazole and miconazole were 90% (9.10), 100% (10.10), 100% (10.10), and 100% (10.10) respectively. Table 3 summarizes the MIC90s of carvacrol compared with fluconazole against drug resistant isolates of C. albicans. Carvacrol was found to have MIC90 of 100-200 µg/ml for drug resistant isolates of C. albicans. Figures 1A and B show the pattern of growth and kill by carvacrol and fluconazole of C. albicans ATCC 10231 and C. albicans CBS 5982, respectively, at concentrations ranging from 2×MIC to ¼×MIC. The results revealed that carvacrol reduced number of C. albicans cells after 2, 4, 6, 8, 12, 24 and 48 compared to untreated control (P≤0.05). In general, time kill curves for C. albicans ATCC 10231 showed decreases 3.73-, 2.99-, 2.47 and 2.23-fold in fungal population size (the log10 CFU) treated with 2×MIC, 1×MIC, 1/2×MIC and ¼×MIC of carvacrol, respectively. C. albicans ATCC 10231 cells were not killed by fluconazole but instead continued to multiply, albeit at a lower rate than untreated control. At 48 th , the log10 CFU value was reduced 4.67-, 3.69-, 3.19 and 3.14-fold in the C. albicans CBS 5982 treated with 2×MIC, 1×MIC, 1/2×MIC and ¼×MIC of carvacrol, respectively. At concentrations ranging from 2×MIC to ¼×MIC, fluconazole reduced the counts by 7.82-to 4.42-fold log10 CFU/ml in C. albicans CBS 5982. To measure the changes in hypha formation we exploited a light microscopy to visualize yeast-hyphal transition indicated that the treatment of preformed hypha with carvacrol resulted in a subtle reduction in yeast-hyphal transition compared to untreated control. As shown in Figure 2 , carvacrol decreased yeasthyphal transition of C. albicans ATCC 10231. Our results indicate that the carvacrol exert their antifungal effect through inhibition of ergosterol biosynthesis in C. albicans ATCC 10231 and C. albicans CBS 5982. At 2×MIC, 1×MIC, ½×MIC and ¼×MIC concentrations, carvacrol reduced 66.4%, 61%, 54.2% and 38.5%, respectively of total ergosterol content in C. albicans ATCC 10231. No significant differences in mean ergosterol content were observed in C. albicans ATCC 10231 grown in the presence of fluconazole (P>0.05). The decrease in ergosterol content of C. albicans CBS 5982 at 2×MIC, 1×MIC, ½×MIC and ¼×MIC of carvacrol were 67%, 61.2%, 52.4% and 43%, respectively. Fluconazole was effective at concentrations ranging from 2×MIC to ¼×MIC and caused 64 to 42% reduction in total ergosterol content in C. albicans CBS 5982 (Figure 3 ). throughput screening has emerged as a tool for biological investigation that could be used to treat the infections (2, 5, 23) . In this study, we show that carvacrol displays potential anti-Candida activity which has been earlier reported to active against C. albicans (6, 8). Our data supports influences of carvacrol in multidrug resistance clinical isolates of C. albicans. Several lines of evidence demonstrate that carvacrol was the most effective compound in killing drug resistant Candida species (24, 25) .
The mechanisms of action of carvacrol was suggested to be the result of its inhibitory activity on membrane integrity of C. albicans and the disruption of ergosterol biosynthesis which may also prove lethal to the C. albicans. It was demonstrated that carvacrol exerts its antifungal effects by mechanisms resembling calcium stress and inhibition of the target of rapamycin signaling pathway (6, 9, 26). The time kill assays performed in this study provide information on the effect of carvacrol on drug resistance C. albicans. Our observation suggests that carvacrol, which not only active on drug resistance C. albicans, also influences growth and kill of Candida cells. The antifungal activity of carvacrol on the drug resistance C. albicans were -able to reduced completely a significant number of yeast forms. In addition, this molecule inhibited the transition from yeast to hyphae cells and also ergosterol content that could decrease the ability of C. albicans cells to cause disease.
The major pathways that is essential for fungal growth include the ergosterol and its biosynthetic pathway. However, the ERG11 gene play key roles in ergosterol biosynthetic pathway (15, 16) .
In this study, the relative gene expression results indicated the inhibitory effect of carvacrol on ERG11 gene that regulate ergosterol synthesis. Akins (26) indicated that the ergosterol biosynthesis genes ERG3 and ERG11 are responsible for antifungal resistance in C. albicans. Khodavandi et al. ) 19(, were demonstrated that the fluconazole in combination with terbinafine significantly reduce the expression of ERG1, 3 and 11 in the cell membrane of C. albicans.
In conclusion, our study demonstrates that carvacrol exhibits potent antifungal activity against drug resistance C. albicans, reduce the number of yeast forms, inhibits hyphae formation, reduce ergosterol content and inhibitory effect of ERG11 gene expression. Because infections due to drug resistance C. albicans are an alarming health problem, these results suggest that carvacrol may have potential applications in the treatment of drug resistance C. albicans infections. Further investigation is needed to gauge the validity of the effect of carvacrol on other significant genes contributing to the cell membrane of C. albicans with different techniques such as next generation sequencing and microarray. 
